Health insurance reimbursement for hyperlipidemic treatment should be modified

The pharmacoeconomic issues of individual antihyperlipidemic agents should be evaluated in terms of various factors, according to the Korean Society of Cardiology and the Korean Society of Lipidology and Atherosclerosis.

In a statement addressed to the Health Insurance Review Agency, the two societies said that the current health insurance allowance for the treatment of hyperlipidemia needs ...